A new method for the direct determination of heparin levels in blood

被引:0
作者
Vogel, V. [1 ]
Haese, C. [1 ]
Baykut, D. [2 ]
Maentele, W. [1 ]
机构
[1] Johann Wolfgang Goethe Univ Frankfurt Main, Fachbereich Phys, Inst Biophys, Max von Laue Str 1, D-60438 Frankfurt, Germany
[2] Univ Spital Basel, Herz Thorax Chirurg, Basel, Switzerland
来源
ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE | 2007年 / 21卷 / 04期
关键词
heparin; blood coagulation; heparin dosage; protamin; light scattering; analytical ultracentrifugation;
D O I
10.1007/s00398-007-0582-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A new, direct and simple method for the determination of heparin levels in blood, based on the complex formation of heparin with protamin, was developed. With excess protamine, heparin forms nano-scaled particles whose sizes range from approx. 100 nm to 200 nm and which can be detected by light-scattering technique. The light-scattering intensity is proportional to the concentration of the particles and, thus, to the concentration of the heparin present. This heparin analysis can be used for fractionated, low-molecular heparins as well as for unfractionated heparins, needing only a small (<1 mL) volume of blood or plasma, respectively. Due to its linearity and sensitivity, the analysis can be applied from low (<10 I.U./kg BM) to high doses (>500 I.E./kg BM) of heparin. Because of the specific reaction of the test to heparin molecules, the disadvantages of several established test methods for blood coagulation (ACT, Hepcon, Heptest etc.) could be eliminated.
引用
收藏
页码:140 / 147
页数:8
相关论文
共 14 条
[1]  
CUNDALL RB, 1982, MAKROMOL CHEM, V183, P849
[2]   TURBIDIMETRIC ESTIMATION OF HEPARIN WITH PROTAMINE [J].
FEKETE, G .
NATURWISSENSCHAFTEN, 1956, 43 (12) :279-280
[3]  
Fischer A, 1935, BIOCHEM Z, V278, P133
[4]  
HAAS S, 1999, NIEDERMOLEKULARE HEP
[5]   Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X [J].
Hardy, JF ;
Belisle, S ;
Robitaille, D ;
Perrault, J ;
Roy, M ;
Gagnon, L .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 112 (01) :154-161
[6]  
Harenberg J, 2004, HAEMOSTASEOLOGIE, V24, P261
[7]  
HORROW JC, 1985, ANESTH ANALG, V64, P348
[8]   Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: Risks and predictors of under-reporting [J].
Kimmel, SE ;
Sekeres, MA ;
Berlin, JA ;
Goldberg, LR ;
Strom, BL .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (01) :1-10
[9]   Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration [J].
Koerber, JM ;
Smythe, MA ;
Begle, RL ;
Mattson, JC ;
Kershaw, BP ;
Westley, SJ .
PHARMACOTHERAPY, 1999, 19 (08) :922-931
[10]  
Kratochvil P., 1972, LIGHT SCATTERING POL, P333